AI Article Synopsis
Article Abstract
Aim: To determine optimal mode of transesophageal pacing for selection of appropriate antiarrhythmic therapy for prevention of attacks of atrial fibrillation and flutter in patients with ischemic heart disease.
Material And Methods: Two hundred eighteen patients with ischemic heart disease and attacks of atrial fibrillation or flutter. Selection of antiarrhythmic drugs was carried out with the use of competitive, rapid, salvos of ultra rapid, and slowly accelerating ultra rapid modes of pacing. Results. Most effective and reproducible method for induction of attacks of atrial flutter and fibrillation was slowly accelerating ultra rapid mode of pacing. Average duration of positive clinical effect of preventive antiarrhythmic therapy selected basing on the results of this mode in patients with ischemic heart disease was 3.1-/+0.3 years. Unfavorable prognostic sign decreasing preventive effect of antiarrhythmic therapy was left atrial dilatation.
Conclusion: Slowly accelerating mode of transesophageal pacing was most effective tool for selection of antiarrhythmic therapy aimed at prevention of attacks of atrial fibrillation and flutter in patients with ischemic heart disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background: The most effective way to treat patients following a first ICD therapy is unclear. We hypothesised that following first ICD therapy, combining different treatment strategies would be associated with a reduction in the risk of subsequent therapy compared to single strategies alone.
Methods: Data was collected from consecutive patients undergoing ICD implantation at King's College Hospital between January 2009 and December 2019.
Atrial arrhythmias with mediastinal lymphadenopathy presentation of isolated atrial myocarditis.
J Arrhythm
February 2025
Department of Electrophysiology, Department of Cardiology AIG Institute of Cardiac Sciences and Research Hyderabad India.
Objectives: We present a case series of patients with granulomatous myocarditis presenting as atrial arrhythmias accompanied by lymphadenopathy.
Background: Atrial myocarditis (AM) may be the cause of atrial fibrillation (AF) in patients without risk factors.
Methods: Patients with atrial fibrillation without risk factors underwent 18F-Fluorodeoxyglucose positron emission tomography (18F-FDG-PET).
Drug Delivery Applications of Hydrophobic Deep Eutectic Solvent-in-Water Nanoemulsions: A Comparative Analysis of Ultrasound Emulsification and Membrane-Assisted Nanoemulsification.
ACS Appl Mater Interfaces
January 2025
Department of Chemical Engineering and Environmental Technology, Universidad de Zaragoza, Campus Río Ebro-Edificio I+D, 50018 Zaragoza, Spain.
The emergence of green chemistry and engineering principles to enforce sustainability aspects has ensured the prevalence of green solvents and green processes. Our study addresses this quest by exploring drug delivery applications of hydrophobic deep eutectic solvents (DESs) which are alternative green solvents. Initially, this work showcases the hydrophobic drug solubilization capabilities of a natural hydrophobic DES, menthol, and decanoic acid.
View Article and Find Full Text PDFPost-operative new-onset atrial fibrillation (POAF) is a possible complication following cardiac surgery. Digoxin is a drug with positive inotropic and negative chronotropic effects and is listed among antiarrhythmic drugs that can be prescribed in dogs with atrial fibrillation. This report aims at describing the use of digoxin in two dogs with persistent POAF after mitral valve repair.
View Article and Find Full Text PDFHealth Care Resource Utilization With Dronedarone Versus Sotalol Following Catheter Ablation in Adults With Atrial Fibrillation.
Clin Cardiol
January 2025
Department of Medicine, Creighton University School of Medicine and CHI Health, Omaha, Nebraska, USA.
Background: Clinical trials support dronedarone use for atrial fibrillation (AF) following catheter ablation (CA); however, comparative data on health care resource utilization (HCRU) with other antiarrhythmic drugs are lacking.
Methods: Retrospective analysis of Merative MarketScan databases (January 01, 2012-March 31, 2020) comparatively assessed HCRU in US adults with AF who received dronedarone or sotalol post-CA. Patients with ≥ 12-months' pre-CA data were followed from post-CA index treatment to disenrollment, death, or study end.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!